
Cemsidomide: Emerging Evidence and Safety Management in Relapsed/Refractory Multiple Myeloma
Dr. Peter Forsberg reviews early-phase data for cemsidomide, a novel cereblon-binding agent that promotes degradation of Ikaros and Aiolos.
Episodes in this series

Dr. Peter Forsberg reviews early-phase data for cemsidomide, a novel cereblon-binding agent that promotes degradation of Ikaros and Aiolos. The open-label phase 1/2 study evaluated cemsidomide with dexamethasone in a heavily pretreated population, with a median of seven prior lines of therapy. Approximately 75% of patients had received prior CAR T-cell therapy or a T-cell engager, and the recommended phase 2 dose demonstrated an overall response rate of 53%. Faculty discuss the potential relevance of these findings for patients with limited treatment options, including those previously exposed to BCMA-directed therapies, while emphasizing that the evidence remains early and does not support direct comparisons with other CELMoDs. The discussion then focuses on safety management, particularly grade 3/4 neutropenia, febrile neutropenia, growth factor support, and infection prophylaxis. Faculty consider proactive versus reactive growth factor use and the potential need for Pneumocystis jirovecii pneumonia prophylaxis in heavily pretreated patients.
Related to this article








